Lifecore Biomedical, Inc. De (LFCR) Income from Continuing Operations (2010 - 2025)

Lifecore Biomedical has reported Income from Continuing Operations for 16 years, with the latest figure at -$15.9 million in Q2 2025.

• On a quarterly basis, Income from Continuing Operations fell 124.72% year-over-year to -$15.9 million in Q2 2025; TTM through May 2025 was -$53.5 million, a 673.29% decrease from a year earlier, with the FY2025 full-year figure at -$38.7 million, down 514.93% from the prior year.
• Income from Continuing Operations was -$15.9 million for Q2 2025 at Lifecore Biomedical, down from -$14.8 million in the prior quarter.
• The five-year high for Income from Continuing Operations was $14.8 million in Q1 2024, with the low at -$37.0 million in Q2 2023.
• Average Income from Continuing Operations over 5 years is -$7.8 million, with a median of -$8.8 million recorded in 2021.
• The sharpest annual moves came in 2021 and 2023: Income from Continuing Operations slumped 1350.9% in 2021, then soared 254.79% in 2023.
• Over 5 years, Income from Continuing Operations stood at $7.5 million in 2021, then slumped by 221.92% to -$9.2 million in 2022, then jumped by 254.79% to $14.2 million in 2023, then sank by 146.14% to -$6.6 million in 2024, then tumbled by 142.34% to -$15.9 million in 2025.
• The last three Income from Continuing Operations figures came in at -$15.9 million (Q2 2025), -$14.8 million (Q1 2025), and -$6.6 million (Q4 2024), per Business Quant data.